Evidence map›Paper›PMID 22771595›Full record

ArticleThe Indian journal of medical research2012

Effects of infliximab on bacterial translocation in experimental acute necrotizing pancreatitis.

Sezai Aydin, A Turan Isik, Bulent Unal, Bilgin Comert, Mustafa Ozyurt, Salih Deveci, Gokhan Ozgur, Omer Cengiz, Ilker Tasci, M Refik Mas

Abstract read
In one paragraph

Article in The Indian journal of medical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Immunomodulatory therapies for acute pancreatitis.World journal of gastroenterology · 2014
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sezai AydinDepartment of Surgery, Guven Hospital, A. Ayranci, Ankara, Turkey.
A Turan Isik
Bulent Unal
Bilgin Comert
Mustafa Ozyurt
Salih Deveci
Gokhan Ozgur
Omer Cengiz
Ilker Tasci
M Refik Mas
Güven Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectivesTranslocation of bacteria from the gut is an important factor in the development of septic complications and mortality in acute pancreatitis (AP). The present study was designed to assess the effects of infliximab treatment on bacterial translocation (BT) in experimental acute necrotizing pancreatitis.

methodsMale Sprague-Dawley rats (n=45) were allocated into three groups. AP was induced in group II (positive control, n=15) and group III (Infliximab; n=15) by retrograde injection of taurocholate into the common biliopancreatic duct. Group I rats (Sham; n=15) received normal saline infusion into the common biliopancreatic duct as placebo. Groups I and II were treated by normal saline and group III was treated with infliximab intraperitoneally on 6, 30 and 54 h after induction of pancreatitis. All surviving animals were killed 60 h after the induction of pancreatitis, and specimens were collected for amylase measurement as well as histopathologic and microbiologic examinations.

resultsOedema, acinar cell necrosis, inflammatory infiltration, haemorrhage, fat necrosis and perivascular inflammation in group III rats were decreased with infliximab treatment when compared with group II (P<0.001). BT to mesentery lymph node in groups I, II and III were 20, 100 and 46 per cent, respectively. BT to peritoneum and pancreas in group III was lower than group II (P<0.05). INTERPRETATION &

conclusionsInfliximab administration resulted in beneficial effects on BT and histopathologic changes in the experimental necrotizing pancreatitis. Whether anti-TNF therapy has a role in prevention of complications of ANP needs to be established.

Indexed as

Antibodies, MonoclonalBacterial TranslocationPancreatitis, Acute NecrotizingAcinar CellsAmylasesAnimalsBacteriaHumansInfliximabMaleModels, AnimalPancreatic DuctsRatsRats, Sprague-DawleyTaurocholic AcidAmylasesAntibodies, MonoclonalInfliximabTaurocholic Acid

Identifiers

PMID22771595
PMCPMC3401696
OpenAlexW1592751167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.